Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

Akamatsu H, Ninomiya K, Kenmotsu H et al (2019) The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 24:731–770. https://doi.org/10.1007/s10147-019-01431-z

Article  PubMed  PubMed Central  Google Scholar 

Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25. https://doi.org/10.1038/cdd.2013.67

CAS  Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

de Rouw N, Boosman RJ, van de Bruinhorst H et al (2020) Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146:30–35. https://doi.org/10.1016/j.lungcan.2020.05.022

Article  PubMed  Google Scholar 

Diem S, Schmid S, Krapf M et al (2017) Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111:176–181. https://doi.org/10.1016/j.lungcan.2017.07.024

Article  PubMed  Google Scholar 

Dumoulin DW, Visser S, Cornelissen R et al (2020) Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC. J Thorac Oncol 15:1472–1483. https://doi.org/10.1016/j.jtho.2020.04.021

CAS  Article  PubMed  Google Scholar 

Ettinger DS, Aisner DL, Wood DE et al (2018) NCCN Guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 16:807–821. https://doi.org/10.6004/jnccn.2018.0062

Article  PubMed  Google Scholar 

Gadgeel S, Rodríguez-Abreu D, Speranza G et al (2020) Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38:1505–1517. https://doi.org/10.1200/JCO.19.03136

CAS  Article  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005

CAS  Article  PubMed  Google Scholar 

Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the Phase I KEYNOTE-001 study. J Clin Oncol 37:2518–2527. https://doi.org/10.1200/JCO.19.00934

CAS  Article  PubMed  PubMed Central  Google Scholar 

Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced Non–small-cell lung cancer. N Engl J Med 381:2020–2031. https://doi.org/10.1056/NEJMoa1910231

CAS  Article  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244

CAS  Article  PubMed  Google Scholar 

Paz-Ares L, de Marinis F, Dediu M et al (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (Paramount): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247–255. https://doi.org/10.1016/S1470-2045(12)70063-3

CAS  Article  PubMed  Google Scholar 

Paz-Ares LG, de Marinis F, Dediu M et al (2013) Paramount: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895–2902. https://doi.org/10.1200/JCO.2012.47.1102

CAS  Article  PubMed  Google Scholar 

Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous Non–small-cell lung cancer. N Engl J Med 379:2040–2051. https://doi.org/10.1056/NEJMoa1810865

CAS  Article  PubMed  Google Scholar 

Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198–211. https://doi.org/10.1016/S1470-2045(20)30641-0

CAS  Article  PubMed  Google Scholar 

Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192–iv237. https://doi.org/10.1093/annonc/mdy275

CAS  Article  PubMed  Google Scholar 

Roselli M, Cereda V, di Bari MG et al (2013) Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2:e27025. https://doi.org/10.4161/onci.27025

Article  PubMed  PubMed Central  Google Scholar 

Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301. https://doi.org/10.1056/NEJMoa1716948

CAS  Article  PubMed  Google Scholar 

Visser S, Huisbrink J, van’t Veer NE et al (2018) Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. https://doi.org/10.1183/13993003.00884-2018

Article  PubMed  Google Scholar 

Wang Z, Till B, Gao Q (2017) Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology 6:e1331807. https://doi.org/10.1080/2162402X.2017.1331807

Article  PubMed  PubMed Central  Google Scholar 

West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924–937. https://doi.org/10.1016/S1470-2045(19)30167-6

CAS  Article  PubMed  Google Scholar 

Ye J, Ji X, Dennis PA et al (2020) Relationship between progression-free survival, objective response rate, and overall survival in clinical trials of PD-1/PD-L1 immune checkpoint blockade: a meta-analysis. Clin Pharmacol Ther 108:1274–1288. https://doi.org/10.1002/cpt.1956

CAS  Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif